Small molecule · Inhibitor of isocitrate dehydrogenase 1 (IDH1) R132 mutant (IDH1) · developed by Nuvation Bio
Safusidenib is an orally available inhibitor that binds and inhibits mutant forms of isocitrate dehydrogenase 1 (IDH1), including the R132 substitution mutations, thereby blocking formation of the oncometabolite 2-hydroxyglutarate. It is being studied in glioma, astrocytoma and oligodendroglioma with IDH1 mutations, and it minimally affects wild-type IDH1.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05303519 | Phase 3 | Glioma | Recruiting | NUVB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Astrocytoma, Grade IVAstrocytoma, IDH-Mutant, Grade 2Astrocytoma, IDH-Mutant, Grade 3Astrocytoma, IDH-Mutant, Grade 4GliomaIDH1-mutant GliomaOligodendrogliomaOligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
Updated Oct 11, 2026. Something wrong or missing? Report it on the NUVB page.
See NUVB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
NUVB catalysts and pipeline →